Overview

Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study

Status:
Not yet recruiting
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
There is significant interest throughout the United States in performing a well-designed study to evaluate whether there is value in using Hydroxychloroquine or Chloroquine as a pre-exposure prophylaxis or post-exposure prophylaxis regimen for COVID-19 patients and at risk personnel. We have designed a prospective double blinded randomized controlled clinical trial to answer just this question. The study will consist of 4 arms: 1. A placebo control arm of 450 patients 2. A low dose prophylaxis arm of 450 patients treated with 200mg Hydroxychloroquine daily 3. A high dose prophylaxis arm of 450 patients treated with 400mg Hydroxychloroquine daily 4. A post-exposure arm of 100 patients treated with 400mg Hydroxychloroquine daily for 7 days.
Phase:
Phase 2
Details
Lead Sponsor:
United States Department of Defense
Treatments:
Hydroxychloroquine